Massachusetts Eye and Ear Infirmary, Harvard Medical School, Ocular Genomics Institute, Boston, MA 02114, USA.
Waisman Center Stem Cell Research Program, University of Wisconsin-Madison, Madison, WI 53705, USA.
Hum Mol Genet. 2020 Apr 15;29(6):967-979. doi: 10.1093/hmg/ddaa016.
Inherited retinal degenerations (IRDs) are at the focus of current genetic therapeutic advancements. For a genetic treatment such as gene therapy to be successful, an accurate genetic diagnostic is required. Genetic diagnostics relies on the assessment of the probability that a given DNA variant is pathogenic. Non-coding variants present a unique challenge for such assessments as compared to coding variants. For one, non-coding variants are present at much higher number in the genome than coding variants. In addition, our understanding of the rules that govern the non-coding regions of the genome is less complete than our understanding of the coding regions. Methods that allow for both the identification of candidate non-coding pathogenic variants and their functional validation may help overcome these caveats allowing for a greater number of patients to benefit from advancements in genetic therapeutics. We present here an unbiased approach combining whole genome sequencing (WGS) with patient-induced pluripotent stem cell (iPSC)-derived retinal organoids (ROs) transcriptome analysis. With this approach, we identified and functionally validated a novel pathogenic non-coding variant in a small family with a previously unresolved genetic diagnosis.
遗传性视网膜变性 (IRDs) 是当前基因治疗进展的重点。为了使基因治疗等遗传治疗取得成功,需要进行准确的遗传诊断。遗传诊断依赖于评估给定 DNA 变体是否具有致病性的可能性。与编码变体相比,非编码变体对这种评估提出了独特的挑战。一方面,非编码变体在基因组中的数量远远高于编码变体。此外,我们对基因组中非编码区域的规则的理解还不如对编码区域的理解完整。允许识别候选非编码致病性变体及其功能验证的方法可能有助于克服这些限制,使更多的患者受益于基因治疗的进步。我们在这里提出了一种结合全基因组测序 (WGS) 和患者诱导多能干细胞 (iPSC) 衍生的视网膜类器官 (RO) 转录组分析的无偏方法。通过这种方法,我们在一个具有先前未解决遗传诊断的小家庭中鉴定并功能验证了一个新的致病性非编码变体。